Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876863 · ClinicalTrials.gov registry record · Phase 2
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00876863 is a Phase 2 study that has completed, run by Sangamo Therapeutics. The registered enrollment target is 49 participants.
The verdict
NCT00876863, a Phase 2 study, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better. CERE-110 uses a virus to transfer a gene that makes Nerve Growth Factor (NGF), a protein that may make nerve cells in the brain healthier and protect them from dying. The virus used in CERE-110 does not cause disease in people. CERE-110 has been carefully studied in laboratory animals and is in the early stages of being tested in people. Fifty patients with mild to moderate Alzheimer's disease will participate in this study. Half of the study subjects will have CERE-110 injected into the brain during a surgical procedure, while the other half will undergo a "placebo" surgery where no medication will be injected. All study participants will be followed for at least two years after surgery.
Interventions
- DRUG CERE-110: Adeno-Associated Virus injection Surgery
- PROCEDURE Placebo Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2008-11 |
| Est. Completion | 2015-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876863
The ClinicalTrials.gov registry entry for NCT00876863 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CERE-110: Adeno-Associated Virus injection Surgery is the first listed.
NCT00876863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00876863 about?
NCT00876863 is a clinical study titled "Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better. CERE-110 uses a virus to transfer a gene that makes Nerve Growth Factor (NGF), a pr...
What is the current status of trial NCT00876863?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2008-11. Estimated completion is 2015-08-13.
What interventions are being tested in trial NCT00876863?
The interventions under investigation include: CERE-110: Adeno-Associated Virus injection Surgery (DRUG), Placebo Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00876863?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.